In the October 2016 issue of European Pharmaceutical Review, Andrew Butcher writes about the emergence of value-based pricing, where the price is determined as a function of measurable “value” brought by the product to relevant stakeholders. He discusses the challenges of measuring value in complex health systems and the importance of understanding the market and engaging a wide group of stakeholders well before a product launches. To read the article, click the link below.
Articles
Understanding today’s drug pricing environment
November 22, 2016
Upcoming events
Swiss Biotech Day 2026
CRA is a proud sponsor of the premier global biotechnology conference for life sciences professionals, fostering international collaboration and impactful...
Informa: EU Pharmaceutical Law Forum 2026
CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical...